According to a recent LinkedIn post from Araceli Biosciences, the company is actively showcasing its technologies at the SLAS conference, emphasizing 3D imaging of organoid growth at ultra high throughput speeds. The post also references scientific work presented by a researcher from the Spicer Lab at The Herbert Wertheim UF Scripps Institute for Biomedical Innovation & Technology on organoid growth analysis.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The post suggests that Araceli is positioning its Endeavor Ultra platform as a live, performance-focused solution, inviting attendees to booth #2312 for demonstrations. For investors, this visibility at a major industry event may support lead generation, customer engagement, and validation of the company’s organoid and high-content imaging capabilities, potentially strengthening its competitive stance in advanced drug discovery workflows.